Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


03.12.2018

2 BMC Cancer
1 Cancer
1 Cancer Res
7 Gynecol Oncol
1 Int J Cancer
1 Oncogene
2 Oncol Rep
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Cancer

  1. LEE IO, Lee JY, Kim HJ, Nam EJ, et al
    Prognostic significance of supradiaphragmatic lymph node metastasis detected by (18)F-FDG PET/CT in advanced epithelial ovarian cancer.
    BMC Cancer. 2018;18:1165.
    PubMed     Text format     Abstract available

  2. RODRIGUEZ-VELAZQUEZ A, Velez R, Lafontaine JC, Colon-Echevarria CB, et al
    Prevalence of breast and ovarian cancer subtypes in Hispanic populations from Puerto Rico.
    BMC Cancer. 2018;18:1177.
    PubMed     Text format     Abstract available


    Cancer

  3. FREY MK, Kopparam RV, Ni Zhou Z, Fields JC, et al
    Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
    Cancer. 2018 Nov 27. doi: 10.1002/cncr.31856.
    PubMed     Text format     Abstract available


    Cancer Res

  4. BUCKLEY MA, Woods NT, Tyrer JP, Mendoza-Fandino G, et al
    Functional analysis and fine mapping of the 9p22.2 ovarian cancer susceptibility locus.
    Cancer Res. 2018 Nov 28. pii: 0008-5472.CAN-17-3864.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  5. SCHLAPPE BA, Weaver AL, Ducie JA, Eriksson AGZ, et al
    Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy.
    Gynecol Oncol. 2018 Aug 31. pii: S0090-8258(18)31152.
    PubMed     Text format     Abstract available

  6. SHENOLIKAR R, Durden E, Meyer N, Lenhart G, et al
    Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
    Gynecol Oncol. 2018 Sep 26. pii: S0090-8258(18)31176.
    PubMed     Text format     Abstract available

  7. HEITZ F, Harter P, Avall-Lundqvist E, Reuss A, et al
    Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.
    Gynecol Oncol. 2018 Nov 19. pii: S0090-8258(18)31406.
    PubMed     Text format     Abstract available

  8. BOLAND JL, Zhou Q, Martin M, Callahan MK, et al
    Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.
    Gynecol Oncol. 2018 Nov 20. pii: S0090-8258(18)31445.
    PubMed     Text format     Abstract available

  9. JAVELLANA M, Hoppenot C, Lengyel E
    The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
    Gynecol Oncol. 2018 Nov 21. pii: S0090-8258(18)31404.
    PubMed     Text format     Abstract available

  10. WAGNER BE, Langstraat CL, McGree ME, Weaver AL, et al
    Beyond prophylaxis: Extended risk of venous thromboembolism following primary debulking surgery for ovarian cancer.
    Gynecol Oncol. 2018 Nov 21. pii: S0090-8258(18)31422.
    PubMed     Text format     Abstract available

  11. SUBRAMANIAM A, Einerson BD, Blanchard CT, Erickson BK, et al
    The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction.
    Gynecol Oncol. 2018 Nov 23. pii: S0090-8258(18)31405.
    PubMed     Text format     Abstract available


    Int J Cancer

  12. KIM S, Wang M, Tyrer JP, Jensen A, et al
    A Comprehensive Gene-Environment Interaction Analysis in Ovarian Cancer using Genome-wide Significant Common Variants.
    Int J Cancer. 2018 Nov 29. doi: 10.1002/ijc.32029.
    PubMed     Text format     Abstract available


    Oncogene

  13. ZHAO L, Wang W, Xu L, Yi T, et al
    Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer.
    Oncogene. 2018 Nov 26. pii: 10.1038/s41388-018-0577.
    PubMed     Text format     Abstract available


    Oncol Rep

  14. MLYNSKA A, Salciuniene G, Zilionyte K, Garberyte S, et al
    Chemokine profiling in serum from patients with ovarian cancer reveals candidate biomarkers for recurrence and immune infiltration.
    Oncol Rep. 2018 Nov 27. doi: 10.3892/or.2018.6886.
    PubMed     Text format     Abstract available

  15. LU DH, Yang J, Gao LK, Min J, et al
    Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelialmesenchymal transition.
    Oncol Rep. 2018 Nov 27. doi: 10.3892/or.2018.6888.
    PubMed     Text format     Abstract available


    PLoS One

  16. PRAHM KP, Hogdall C, Karlsen MA, Christensen IJ, et al
    Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer.
    PLoS One. 2018;13:e0207319.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: